Double-blind, placebo-controlled, randomized, dose-finding trial to determine the safety and efficacy of three dose levels of EMA401 in reducing the 24-hour mean pain intensity score in patients with postherpetic neuralgia (EMPHENE)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: NOVARTIS FARMACEUTICA, SA
- Phase: II
- Execution start: 21/07/2017
- End of execution: 30/09/2019
- PI: RAFAEL GALVEZ MATEOS